JP2005104960A - Internal liquid agent and taste quality change-preventing liquid agent for glucuronolactone-containing solution - Google Patents
Internal liquid agent and taste quality change-preventing liquid agent for glucuronolactone-containing solution Download PDFInfo
- Publication number
- JP2005104960A JP2005104960A JP2004055319A JP2004055319A JP2005104960A JP 2005104960 A JP2005104960 A JP 2005104960A JP 2004055319 A JP2004055319 A JP 2004055319A JP 2004055319 A JP2004055319 A JP 2004055319A JP 2005104960 A JP2005104960 A JP 2005104960A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- glucuronolactone
- liquid
- internal use
- hydrochloric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 93
- UYUXSRADSPPKRZ-UHFFFAOYSA-N D-glucuronic acid gamma-lactone Natural products O=CC(O)C1OC(=O)C(O)C1O UYUXSRADSPPKRZ-UHFFFAOYSA-N 0.000 title claims abstract description 74
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 title claims abstract description 74
- 229950002441 glucurolactone Drugs 0.000 title claims abstract description 74
- 235000019640 taste Nutrition 0.000 title claims abstract description 48
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 120
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims abstract description 117
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims abstract description 59
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 34
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 19
- 150000007524 organic acids Chemical class 0.000 claims description 13
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 10
- 235000015165 citric acid Nutrition 0.000 claims description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 10
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 9
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 8
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 8
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 7
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 6
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 5
- 235000011054 acetic acid Nutrition 0.000 claims description 5
- 235000014655 lactic acid Nutrition 0.000 claims description 5
- 239000004310 lactic acid Substances 0.000 claims description 5
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 5
- 239000011976 maleic acid Substances 0.000 claims description 5
- 239000011975 tartaric acid Substances 0.000 claims description 5
- 235000002906 tartaric acid Nutrition 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 4
- 239000001361 adipic acid Substances 0.000 claims description 4
- 235000011037 adipic acid Nutrition 0.000 claims description 4
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 4
- 239000001530 fumaric acid Substances 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000000174 gluconic acid Substances 0.000 claims description 3
- 235000012208 gluconic acid Nutrition 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 9
- 230000003908 liver function Effects 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 3
- 238000004321 preservation Methods 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 229960004106 citric acid Drugs 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- -1 pH adjusters Substances 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 5
- 229960002920 sorbitol Drugs 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 4
- 230000002335 preservative effect Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 229960001367 tartaric acid Drugs 0.000 description 4
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 241000202807 Glycyrrhiza Species 0.000 description 3
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 3
- 229960000250 adipic acid Drugs 0.000 description 3
- 229960005261 aspartic acid Drugs 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 229940010454 licorice Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 229960001790 sodium citrate Drugs 0.000 description 3
- 235000011083 sodium citrates Nutrition 0.000 description 3
- 229940037001 sodium edetate Drugs 0.000 description 3
- 229960004025 sodium salicylate Drugs 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 2
- JWAZRIHNYRIHIV-UHFFFAOYSA-N 2-naphthol Chemical compound C1=CC=CC2=CC(O)=CC=C21 JWAZRIHNYRIHIV-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004288 Sodium dehydroacetate Substances 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- KPQJOKRSYYJJEL-VLQRKCJKSA-K [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O Chemical compound [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O KPQJOKRSYYJJEL-VLQRKCJKSA-K 0.000 description 2
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 2
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 2
- 229960004543 anhydrous citric acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 235000012209 glucono delta-lactone Nutrition 0.000 description 2
- 239000000182 glucono-delta-lactone Substances 0.000 description 2
- 229960003681 gluconolactone Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229960000448 lactic acid Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 2
- 239000000347 magnesium hydroxide Substances 0.000 description 2
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 2
- 235000012254 magnesium hydroxide Nutrition 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000003002 pH adjusting agent Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 229960000969 phenyl salicylate Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000010241 potassium sorbate Nutrition 0.000 description 2
- 239000004302 potassium sorbate Substances 0.000 description 2
- 229940069338 potassium sorbate Drugs 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 2
- 229940079839 sodium dehydroacetate Drugs 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- CSTRPYAGFNTOEQ-MGMRMFRLSA-N (2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one;octadecanoic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O.CCCCCCCCCCCCCCCCCC(O)=O CSTRPYAGFNTOEQ-MGMRMFRLSA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- OWFBTOBONSHHKE-UHFFFAOYSA-N 2-aminoacetic acid;propane-1,2,3-triol Chemical compound NCC(O)=O.OCC(O)CO OWFBTOBONSHHKE-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000004287 Dehydroacetic acid Substances 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 240000006927 Foeniculum vulgare Species 0.000 description 1
- 235000004204 Foeniculum vulgare Nutrition 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 244000267823 Hydrangea macrophylla Species 0.000 description 1
- 235000014486 Hydrangea macrophylla Nutrition 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- ILRKKHJEINIICQ-OOFFSTKBSA-N Monoammonium glycyrrhizinate Chemical compound N.O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ILRKKHJEINIICQ-OOFFSTKBSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229950011260 betanaphthol Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 235000019258 dehydroacetic acid Nutrition 0.000 description 1
- 229940061632 dehydroacetic acid Drugs 0.000 description 1
- JEQRBTDTEKWZBW-UHFFFAOYSA-N dehydroacetic acid Chemical compound CC(=O)C1=C(O)OC(C)=CC1=O JEQRBTDTEKWZBW-UHFFFAOYSA-N 0.000 description 1
- PGRHXDWITVMQBC-UHFFFAOYSA-N dehydroacetic acid Natural products CC(=O)C1C(=O)OC(C)=CC1=O PGRHXDWITVMQBC-UHFFFAOYSA-N 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- 229950010030 dl-alanine Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- 239000004318 erythorbic acid Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 229940026239 isoascorbic acid Drugs 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940105082 medicinal charcoal Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229950001574 riboflavin phosphate Drugs 0.000 description 1
- 229940109850 royal jelly Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- LLVQEXSQFBTIRD-OTWIGTIJSA-M sodium (2S,3S)-2,3,4-trihydroxy-4-oxobutanoate hydrate Chemical compound O.[Na+].O[C@@H]([C@H](O)C([O-])=O)C(O)=O LLVQEXSQFBTIRD-OTWIGTIJSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940001593 sodium carbonate Drugs 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 229940100515 sorbitan Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 235000001508 sulfur Nutrition 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- CCXAYLQLOLXXKE-DWJAGBRCSA-K trisodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxylato-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-t Chemical compound [Na+].[Na+].[Na+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C([O-])=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O CCXAYLQLOLXXKE-DWJAGBRCSA-K 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明は、肝機能改善能を有するグルクロノラクトンを含有し、かつ保存条件によらず長期間に亘って味質の変化が少ない内服用液剤、及びグルクロノラクトン含有溶液の味質変化防止液剤に関する。 The present invention relates to a liquid for internal use containing glucuronolactone having an ability to improve liver function and having little change in taste over a long period of time regardless of storage conditions, and a liquid for preventing taste change in a solution containing glucuronolactone About.
従来より、肝機能改善成分として、グルクロノラクトンが知られており、ビタミンB群等と共に、ドリンク剤等に配合されている(例えば、特許文献1参照)。
しかしながら、前記グルクロノラクトンを配合した従来のドリンク剤は、経時的にいわゆる「えぐみ」が生じ、味質が変化し、飲み難くなるという問題がある。肝機能改善能を有するグルクロノラクトンを含有し、かつ保存条件によらず長期間に亘って味質の変化が少ない内服用液剤、及びグルクロノラクトン含有溶液の味質変化防止液剤は、未だ提供されていないのが現状である。
Conventionally, glucuronolactone has been known as a liver function improving component, and is blended in drinks and the like together with vitamin B group and the like (see, for example, Patent Document 1).
However, the conventional drink containing the glucuronolactone has a problem that so-called “egumi” occurs over time, the taste quality changes, and it becomes difficult to drink. A liquid for internal use that contains glucuronolactone that has the ability to improve liver function and has little change in taste over a long period of time regardless of storage conditions, and a liquid that prevents changes in taste of glucuronolactone-containing solutions are still available The current situation is not.
本発明は、前記従来における問題を解決し、以下の目的を達成することを課題とする。即ち、本発明は、肝機能改善能を有するグルクロノラクトンを配合し、かつ保存条件によらず長期間に亘って味質の変化が少ない内服用液剤、及びグルクロノラクトン含有溶液の味質変化防止液剤を提供することを目的とする。 An object of the present invention is to solve the conventional problems and achieve the following objects. That is, the present invention comprises glucuronolactone having an ability to improve liver function, and a liquid for internal use with little change in taste over a long period of time regardless of storage conditions, and a change in taste of a solution containing glucuronolactone An object is to provide a preventive liquid.
前記課題を解決するための手段としては、以下の通りである。即ち、
<1> グルクロノラクトンと、塩酸及びリン酸の少なくともいずれかとを含有してなることを特徴とする内服用液剤である。該<1>に記載の内服用液剤においては、前記塩酸及びリン酸の少なくともいずれかにより味質が長期間に亘って一定に維持される。
<2> グルクロノラクトンの含有量が、0.01〜6.7質量%である前記<1>に記載の内服用液剤である。該<2>に記載の内服用液剤においては、前記グルクロノラクトンの含有量が所定の範囲内であるので、味質が長期間に亘って一定に維持される。
<3> 内服用液剤における塩酸及びリン酸のうち、該塩酸を単独で使用した場合の該塩酸の含有量が、0.2×10−3〜1.0体積%である前記<1>から<2>のいずれかに記載の内服用液剤である。該<3>に記載の内服用液剤においては、前記塩酸の含有量が所定の範囲内であるので、味質が長期間に亘って一定にかつ良好に維持される。
<4> 内服用液剤における塩酸及びリン酸のうち、該リン酸を単独で使用した場合の該リン酸の含有量が、0.4×10−3〜2.0質量%である前記<1>から<2>のいずれかに記載の内服用液剤である。該<4>に記載の内服用液剤においては、前記リン酸の含有量が所定の範囲内であるので、味質が長期間に亘って一定にかつ良好に維持される。
<5> 内服用液剤における塩酸及びリン酸を含有する場合の該塩酸及びリン酸の含有量が、前記塩酸の含有量×a+前記リン酸の含有量×b (但し、a+b≧1)である前記<1>から<2>のいずれかに記載の内服用液剤である。該<5>に記載の内服用液剤においては、前記塩酸及びリン酸の含有量が所定の範囲内であるので、味質が長期間に亘って一定にかつ良好に維持される。
<6> グルクロノラクトン(mg)と塩酸(ml)との比が、前記塩酸1mlに対して前記グルクロノラクトンが5.0×104mg以下である前記<1>から<3>及び<5>のいずれかに記載の内服用液剤である。該<6>に記載の内服用液剤においては、前記グルクロノラクトンと前記塩酸との比が所定の範囲内であるので、味質が長期間に亘って一定にかつ良好に維持される。
<7> グルクロノラクトン(mg)とリン酸(mg)との比が、前記リン酸1mgに対して前記グルクロノラクトンが2.5×104mg以下である前記<1>から<2>及び<4>から<5>のいずれかに記載の内服用液剤である。該<7>に記載の内服用液剤においては、前記グルクロノラクトンと前記リン酸との比が所定の範囲内であるので、味質が長期間に亘って一定にかつ良好に維持される。
<8> グルクロノラクトン(mg)と、塩酸(ml)及びリン酸(mg)との比が、前記塩酸a(ml)+前記リン酸2b(mg) (但し、a+b=1)に対して前記グルクロノラクトンが5.0×104mg以下である前記<1>から<2>及び<5>のいずれかに記載の内服用液剤である。該<8>に記載の内服用液剤においては、前記グルクロノラクトンと、前記塩酸及びリン酸との比が所定の範囲内であるので、味質が長期間に亘って一定にかつ良好に維持される。
<9> 有機酸を更に含有してなる前記<1>から<8>のいずれかに記載の内服用液剤である。該<9>に記載の内服用液剤では、前記有機酸により、酸味が適度に調整されており、飲み易い。
<10> 有機酸が、リンゴ酸、クエン酸、アスパラギン酸、グルタミン酸、アジピン酸、グルコン酸、酒石酸、コハク酸、乳酸、酢酸、マレイン酸及びフマル酸から選択される少なくとも1種である前記<9>に記載の内服用液剤である。該<10>に記載の内服用液剤では、前記有機酸により、酸味が適度に調整され、かつ該有機酸自体による薬効が付加される。
<11> 有機酸の内服用液剤における含有量が、10mg/50ml〜2,000mg/50mlである前記<9>から<10>のいずれかに記載の内服用液剤である。該<11>に記載の内服用液剤では、前記有機酸の含有量が所定の範囲内であるので、酸味がより適度に調整されており、飲み易く、また、薬効的にも優れる。
<12> グルクロノラクトンを含有してなり、塩酸及びリン酸の少なくともいずれかにより味質変化が抑制されたことを特徴とする内服用液剤である。該<12>に記載の内服用液剤においては、該内服用液剤における味質変化が、前記塩酸及びリン酸の少なくともいずれかにより、長期間に亘って防止される。
<13> 塩酸及びリン酸の少なくともいずれかを含有することを特徴とするグルクロノラクトン含有溶液の味質変化防止液剤である。該<13>に記載のグルクロノラクトン含有溶液の味質変化防止液剤においては、前記塩酸及びリン酸の少なくともいずれかにより、味質変化が長期間に亘って防止される。
Means for solving the problems are as follows. That is,
<1> A liquid for internal use comprising glucuronolactone and at least one of hydrochloric acid and phosphoric acid. In the internal use liquid preparation described in <1>, the taste quality is kept constant over a long period of time by at least one of the hydrochloric acid and phosphoric acid.
<2> The liquid for internal use according to <1>, wherein the content of glucuronolactone is 0.01 to 6.7% by mass. In the internal use liquid preparation described in <2>, since the content of the glucuronolactone is within a predetermined range, the taste quality is kept constant over a long period of time.
<3> Of the hydrochloric acid and phosphoric acid in the internal use liquid preparation, the content of the hydrochloric acid when the hydrochloric acid is used alone is 0.2 × 10 −3 to 1.0% by volume. <2> A liquid preparation for internal use according to any one of the above. In the internal use liquid preparation described in <3>, since the content of the hydrochloric acid is within a predetermined range, the taste quality is maintained constant and well over a long period of time.
<4> Of the hydrochloric acid and phosphoric acid in the liquid for internal use, the content of the phosphoric acid when the phosphoric acid is used alone is 0.4 × 10 −3 to 2.0% by mass <1 > To <2>. In the internal use liquid preparation described in <4>, since the content of the phosphoric acid is within a predetermined range, the taste quality is maintained constant and well over a long period of time.
<5> The content of the hydrochloric acid and phosphoric acid in the case of containing the hydrochloric acid and phosphoric acid in the liquid for internal use is the content of the hydrochloric acid × a + the content of the phosphoric acid × b (provided that a + b ≧ 1) The liquid for internal use according to any one of <1> to <2>. In the internal use liquid preparation described in <5>, since the contents of the hydrochloric acid and phosphoric acid are within a predetermined range, the taste quality is maintained constant and well over a long period of time.
<6> The ratio of glucuronolactone (mg) to hydrochloric acid (ml) is such that the glucuronolactone is 5.0 × 10 4 mg or less with respect to 1 ml of the hydrochloric acid. 5> The liquid for internal use as described in any one of 5>. In the internal use liquid preparation described in <6>, since the ratio of the glucuronolactone to the hydrochloric acid is within a predetermined range, the taste quality is maintained constant and well over a long period of time.
<7> From the above <1> to <2>, wherein the ratio of glucuronolactone (mg) to phosphoric acid (mg) is 2.5 × 10 4 mg or less with respect to 1 mg of phosphoric acid. And <4> to <5>. In the internal use liquid preparation described in <7>, since the ratio of the glucuronolactone and the phosphoric acid is within a predetermined range, the taste quality is maintained constant and well over a long period of time.
<8> The ratio of glucuronolactone (mg) to hydrochloric acid (ml) and phosphoric acid (mg) is based on the hydrochloric acid a (ml) + phosphoric acid 2b (mg) (provided that a + b = 1) The liquid for internal use according to any one of <1> to <2> and <5>, wherein the glucuronolactone is 5.0 × 10 4 mg or less. In the liquid preparation for internal use described in <8>, since the ratio of the glucuronolactone to the hydrochloric acid and phosphoric acid is within a predetermined range, the taste quality is constantly and well maintained over a long period of time. Is done.
<9> The liquid for internal use according to any one of <1> to <8>, further containing an organic acid. In the internal use liquid preparation described in <9>, the acidity is appropriately adjusted by the organic acid, and it is easy to drink.
<10> The aforementioned <9, wherein the organic acid is at least one selected from malic acid, citric acid, aspartic acid, glutamic acid, adipic acid, gluconic acid, tartaric acid, succinic acid, lactic acid, acetic acid, maleic acid and fumaric acid > For internal use. In the internal use liquid preparation described in <10>, the acidity is appropriately adjusted by the organic acid, and the medicinal effect of the organic acid itself is added.
<11> The liquid for internal use according to any one of <9> to <10>, wherein the content of the organic acid in the liquid for internal use is 10 mg / 50 ml to 2,000 mg / 50 ml. In the internal use liquid preparation described in <11>, since the content of the organic acid is within a predetermined range, the acidity is more appropriately adjusted, and it is easy to drink and has excellent medicinal properties.
<12> A liquid preparation for internal use comprising glucuronolactone, wherein taste change is suppressed by at least one of hydrochloric acid and phosphoric acid. In the internal use liquid preparation described in <12>, a taste change in the internal use liquid preparation is prevented over a long period of time by at least one of the hydrochloric acid and phosphoric acid.
<13> A solution for preventing change in taste of a glucuronolactone-containing solution, characterized by containing at least one of hydrochloric acid and phosphoric acid. In the taste change preventing liquid preparation of the glucuronolactone-containing solution according to <13>, taste change is prevented over a long period of time by at least one of the hydrochloric acid and phosphoric acid.
本発明によると、従来における問題を解決することができ、保存条件によらず長期間に亘って味質の変化が少ない内服用液剤、及びグルクロノラクトン含有溶液の味質変化防止液剤を提供することができる。 ADVANTAGE OF THE INVENTION According to this invention, the problem in the past can be solved, and the internal use liquid agent with little change of taste quality over a long period of time regardless of a preservation | save condition, and the taste change prevention liquid agent of a glucuronolactone containing solution are provided. be able to.
(内服用液剤)
本発明の内服用液剤は、グルクロノラクトンと、塩酸及びリン酸の少なくともいずれかとを含有してなり、更に必要に応じて有機酸、及びその他の成分を含有してなる。
(Liquid preparation for internal use)
The liquid for internal use of the present invention contains glucuronolactone and at least one of hydrochloric acid and phosphoric acid, and further contains an organic acid and other components as necessary.
−グルクロノラクトン−
前記グルクロノラクトンは、肝臓の働きをよくする成分であり、具体的には、肝臓の血流を増やし、解毒能力を高める効果を有し、副作用がほとんどなく、じん麻疹、湿疹、妊娠中毒などにも適用可能である。
-Glucuronolactone-
The glucuronolactone is a component that improves the function of the liver. Specifically, it has the effect of increasing the blood flow of the liver and enhancing the detoxification ability, has almost no side effects, such as urticaria, eczema, pregnancy intoxication, etc. It is also applicable to.
前記グルクロノラクトンは、下記構造式(1)で表され、性状は、白色〜微黄白色の結晶又は結晶性の粉末である。また、pHが4以上の条件になると不安定になる。 The glucuronolactone is represented by the following structural formula (1), and the properties are white to slightly yellowish white crystals or crystalline powder. Moreover, it becomes unstable when the pH is 4 or more.
前記グルクロノラクトンは、市販品であってもよいし、適宜合成したものであってもよい。なお、前記グルクロノラクトンを合成する方法としては、特に制限はなく、目的に応じて適宜選択することができる。 The glucuronolactone may be a commercially available product or an appropriately synthesized product. The method for synthesizing the glucuronolactone is not particularly limited and may be appropriately selected depending on the intended purpose.
前記グルクロノラクトンの前記内服用液剤における含有量としては、特に制限はなく、目的に応じて適宜選択することができるが、質量%単位では、例えば、0.01〜6.7質量%が好ましく、0.02〜3.4質量%がより好ましい。また、mg/ml単位では、例えば、5mg/50ml〜2,000mg/30mlが好ましく、10mg/50ml〜1,000mg/30mlがより好ましい。 There is no restriction | limiting in particular as content in the said liquid for internal use of the said glucuronolactone, Although it can select suitably according to the objective, For example, 0.01-6.7 mass% is preferable in a mass% unit. 0.02-3.4 mass% is more preferable. Moreover, in mg / ml unit, for example, 5 mg / 50 ml to 2,000 mg / 30 ml is preferable, and 10 mg / 50 ml to 1,000 mg / 30 ml is more preferable.
−塩酸及びリン酸の少なくともいずれか−
前記塩酸及びリン酸の少なくともいずれかにより、前記グルクロノラクトンを含有する前記内服用液剤における味質変化が抑制される。
前記塩酸及びリン酸は、前記塩酸単独でもよいし、前記リン酸単独でもよく、また、これらを併用してもよいが、前記塩酸単独がより好ましい。
前記塩酸を単独で使用した場合の前記内服用液剤における該塩酸の含有量としては、特に制限はなく、目的に応じて適宜選択することができるが、例えば、36%塩酸で、0.2×10−3〜1.0体積%が好ましく、0.2×10−2〜0.5体積%がより好ましい。
-At least one of hydrochloric acid and phosphoric acid-
By at least one of the hydrochloric acid and phosphoric acid, the taste quality change in the liquid for internal use containing the glucuronolactone is suppressed.
The hydrochloric acid and phosphoric acid may be the hydrochloric acid alone, the phosphoric acid alone, or a combination thereof, but the hydrochloric acid alone is more preferable.
The content of the hydrochloric acid in the liquid for internal use when the hydrochloric acid is used alone is not particularly limited and may be appropriately selected depending on the intended purpose. 10 < -3 > -1.0 volume% is preferable and 0.2 * 10 <-2 > -0.5 volume% is more preferable.
前記グルクロノラクトン(mg)と塩酸(ml)との比(グルクロノラクトン:塩酸)としては、特に制限はなく、目的に応じて適宜選択することができるが、例えば、前記塩酸1mlに対して前記グルクロノラクトンが5.0×104mg以下が好ましく、2.5×104mg以下がより好ましい。 The ratio of glucuronolactone (mg) to hydrochloric acid (ml) (glucuronolactone: hydrochloric acid) is not particularly limited and may be appropriately selected depending on the intended purpose. The glucuronolactone is preferably 5.0 × 10 4 mg or less, and more preferably 2.5 × 10 4 mg or less.
前記リン酸単独で使用した場合の前記内服用液剤における該リン酸の含有量としては、特に制限はなく、目的に応じて適宜選択することができるが、例えば、85%リン酸で、0.4×10―3〜2.0質量%が好ましく、0.4×10−2〜1.5質量%がより好ましい。 There is no restriction | limiting in particular as content of this phosphoric acid in the said internal use liquid agent at the time of using the said phosphoric acid alone, Although it can select suitably according to the objective, For example, it is 85% phosphoric acid, and is 0.00. 4 * 10 < -3 > -2.0 mass% is preferable, and 0.4 * 10 <-2 > -1.5 mass% is more preferable.
前記グルクロノラクトン(mg)とリン酸(mg)との比(グルクロノラクトン:リン酸)としては、特に制限はなく、目的に応じて適宜選択することができるが、例えば、前記リン酸1mgに対して前記グルクロノラクトンが2.5×104mg以下が好ましい。 The ratio of glucuronolactone (mg) to phosphoric acid (mg) (glucuronolactone: phosphoric acid) is not particularly limited and may be appropriately selected depending on the intended purpose. For example, 1 mg of phosphoric acid The glucuronolactone is preferably 2.5 × 10 4 mg or less.
前記塩酸及びリン酸を含有する場合の前記内服用液剤における該塩酸及びリン酸の含有量としては、特に制限はなく、目的に応じて適宜選択することができるが、例えば、前記塩酸の含有量×a+前記リン酸の含有量×b (但し、a+b≧1)、であることが好ましい。 There is no restriction | limiting in particular as content of this hydrochloric acid and phosphoric acid in the said liquid for internal use in the case of containing the said hydrochloric acid and phosphoric acid, Although it can select suitably according to the objective, For example, content of the said hydrochloric acid Xa + Phosphoric acid content × b (where a + b ≧ 1).
前記グルクロノラクトン(mg)と、前記塩酸(ml)及びリン酸(mg)との比としては、特に制限はなく、目的に応じて適宜選択することができるが、例えば、前記塩酸a(ml)+前記リン酸2b(mg) (但し、a+b=1)に対して前記グルクロノラクトンが5.0×104mg以下が好ましい。 The ratio of the glucuronolactone (mg) to the hydrochloric acid (ml) and phosphoric acid (mg) is not particularly limited and may be appropriately selected depending on the intended purpose. For example, the hydrochloric acid a (ml ) + Phosphoric acid 2b (mg) (where a + b = 1), but the glucuronolactone is preferably 5.0 × 10 4 mg or less.
−有機酸−
前記有機酸は、前記内服用液剤の酸味を調整する働きを有する。
前記有機酸としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、リンゴ酸、クエン酸、アスパラギン酸、グルタミン酸、アジピン酸、グルコン酸、酒石酸、コハク酸、乳酸、酢酸、マレイン酸、フマル酸などが挙げられる。これらの中でも、クエン酸、及びDL−リンゴ酸が、酸味が良好である点で好ましい。これらは、1種単独で使用してもよいし、2種以上を併用してもよい。
-Organic acid-
The organic acid has a function of adjusting the sourness of the liquid for internal use.
The organic acid is not particularly limited and may be appropriately selected depending on the intended purpose.For example, malic acid, citric acid, aspartic acid, glutamic acid, adipic acid, gluconic acid, tartaric acid, succinic acid, lactic acid, acetic acid, Examples include maleic acid and fumaric acid. Among these, citric acid and DL-malic acid are preferable in terms of good acidity. These may be used individually by 1 type and may use 2 or more types together.
前記有機酸の本発明の前記内服用液剤における含有量としては、特に制限はなく、目的に応じて適宜選択することができるが、mg/ml単位では、例えば、10mg/50ml〜2,000mg/50mlが好ましく、100mg/50ml〜1,000mg/50mlがより好ましい。また、質量%単位では、例えば、0.02〜4質量%が好ましく、0.2〜2質量%がより好ましい。 The content of the organic acid in the liquid for internal use of the present invention is not particularly limited and may be appropriately selected depending on the intended purpose. However, in mg / ml units, for example, 10 mg / 50 ml to 2,000 mg / 2,000 50 ml is preferable, and 100 mg / 50 ml to 1,000 mg / 50 ml is more preferable. Moreover, in the mass% unit, 0.02-4 mass% is preferable, for example, and 0.2-2 mass% is more preferable.
−その他の成分−
前記その他の成分としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、ビタミン類、甘味剤、保存剤、安定化剤、pH調整剤、防腐剤、可溶化剤、矯味剤、溶剤、溶解補助剤、懸濁剤、酸化防止剤、着香剤・香料、生薬、清涼化剤、着色剤、緩衝剤、カフェイン、ローヤルゼリー、などが挙げられる。
なお、前記塩酸及びリン酸は、保存剤、安定剤、pH調整剤、防腐剤、可溶化剤、矯味剤、溶剤、溶解補助剤、懸濁剤等の前記その他の成分として添加されていてもよく、これらの場合にも本発明の効果を奏することができる。
-Other ingredients-
The other components are not particularly limited and may be appropriately selected depending on the purpose. For example, vitamins, sweeteners, preservatives, stabilizers, pH adjusters, preservatives, solubilizers, taste masking Agents, solvents, solubilizers, suspending agents, antioxidants, flavoring agents / fragrances, herbal medicines, cooling agents, coloring agents, buffering agents, caffeine, royal jelly, and the like.
The hydrochloric acid and phosphoric acid may be added as other components such as a preservative, a stabilizer, a pH adjuster, a preservative, a solubilizer, a corrigent, a solvent, a solubilizer, and a suspending agent. In these cases, the effects of the present invention can be achieved.
前記ビタミン類としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、ビタミンA;硝酸チアミン等のビタミンB1;リン酸リボフラビン等のビタミンB2;ニコチン酸アミド等のビタミンB3;塩酸ピリドキシン等のビタミンB6;ビタミンB12、ビタミンD、ビタミンE、アスコルビン酸等のビタミンC;パントテン酸カルシウム、などが挙げられる。これらは、1種単独で使用してもよいし、2種以上を併用してもよい。 The vitamins are not particularly limited and may be appropriately selected depending on the intended purpose. For example, vitamin A; vitamin B1 such as thiamine nitrate; vitamin B2 such as riboflavin phosphate; vitamin B3 such as nicotinamide; Vitamin B6 such as pyridoxine hydrochloride; vitamin B12, vitamin D, vitamin E, vitamin C such as ascorbic acid; calcium pantothenate, and the like. These may be used individually by 1 type and may use 2 or more types together.
前記甘味剤としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、アスパルテーム、アマチャ、アマチャ末、カンゾウ、カンゾウエキス、カンゾウ粗エキス、カンゾウ末、液糖、果糖、果糖ブドウ糖液、ブドウ糖果糖液糖、還元麦芽糖水アメ、グリシン、グリセリン、グリチルリチン酸二カリウム、グリチルリチン酸二ナトリウム、グリチルリチン酸三ナトリウム、グリチルリチン酸モノアンモニウム、黒砂糖、高果糖液糖、ブドウ糖、粉末還元麦芽糖水アメ、水アメ、高ブドウ糖水アメ、乳糖、白糖、精製白糖、精製白糖球状顆粒、ハチミツ、精製ハチミツ、サッカリン、サッカリンナトリウム、ステビア、スクラロース、エリスリトール、キシリトール、D−ソルビトール、D−ソルビトール液、マルチトール、マルチトール液、マルトース、D−マンニトール、単シロップ、アセスルファムカリウム、などが挙げられる。これらは、1種単独で使用してもよいし、2種以上を併用してもよい。 The sweetener is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include aspartame, amateur, amacha powder, licorice, licorice extract, licorice crude extract, licorice powder, liquid sugar, fructose, and fructose glucose. Liquid, glucose fructose liquid sugar, reduced maltose water candy, glycine, glycerin, dipotassium glycyrrhizinate, disodium glycyrrhizinate, trisodium glycyrrhizinate, monoammonium glycyrrhizinate, brown sugar, high fructose liquid sugar, glucose, powdered reduced maltose water Candy, water candy, high glucose water candy, lactose, sucrose, purified sucrose, purified sucrose spherical granules, honey, purified honey, saccharin, saccharin sodium, stevia, sucralose, erythritol, xylitol, D-sorbitol, D-sorbitol solution, maltitol , Ma Chitoru solution, maltose, D- mannitol, simple syrup, acesulfame potassium, and the like. These may be used individually by 1 type and may use 2 or more types together.
前記保存剤としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、安息香酸、安息香酸ナトリウム、エタノール、エデト酸ナトリウム、乾燥亜硫酸ナトリウム、クエン酸、グリセリン、サリチル酸、サリチル酸ナトリウム、ジブチルヒドロキシトルエン、D−ソルビトール、ソルビン酸、ソルビン酸カリウム、デヒドロ酢酸ナトリウム、パラオキシ安息香酸イソブチル、パラオキシ安息香酸イソプロピル、パラオキシ安息香酸エチル、パラオキシ安息香酸ブチル、パラオキシ安息香酸プロピル、パラオキシ安息香酸メチル、プロピレングリコール、などが挙げられる。これらは、1種単独で使用してもよいし、2種以上を併用してもよい。 The preservative is not particularly limited and may be appropriately selected depending on the intended purpose. For example, benzoic acid, sodium benzoate, ethanol, sodium edetate, dried sodium sulfite, citric acid, glycerin, salicylic acid, sodium salicylate , Dibutylhydroxytoluene, D-sorbitol, sorbic acid, potassium sorbate, sodium dehydroacetate, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, ethyl paraoxybenzoate, butyl paraoxybenzoate, propyl paraoxybenzoate, methyl paraoxybenzoate, And propylene glycol. These may be used individually by 1 type and may use 2 or more types together.
前記安定化剤としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、アジピン酸、アスコルビン酸、L−アスコルビン酸ステアリン酸エステル、L−アスコルビン酸ナトリウム、L−アスパラギン酸、L−アスパラギン酸ナトリウム、アミノエチルスルホン酸、DL−アラニン、亜硫酸水素ナトリウム、亜硫酸ナトリウム、L−アルギニン、アルギン酸ナトリウム、アルギン酸プロピレングリコール、アルブミン、安息香酸、安息香酸ナトリウム、イオウ、イノシトール、ウイキョウ末、エタノール、エデト酸カルシウム二ナトリウム、エデト酸ナトリウム、エリソルビン酸、エルソルビン酸ナトリウム、塩化カルシウム、塩化ナトリウム、塩化マグネシウム、塩酸システイン、カカオ脂、果糖、カルボキシビニルポリマー、カルメロースカルシウム、カルメロースナトリウム、含水二酸化ケイ素、乾燥亜硫酸ナトリウム、乾燥水酸化アルミニウムゲル、乾燥水酸化アルミニウムゲル、乾燥炭酸ナトリウム、キサンタンガム、キシリトール、クエン酸、クエン酸カルシウム、クエン酸ナトリウム、グリシン、グリセリン、グリセリン脂肪酸エステル、グリチルリチン酸二ナトリウム、グルコノ−δ−ラクトン、グルコン酸カルシウム、軽質無水ケイ酸、ケイヒ末、結晶セルロース、酢酸、酢酸トコフェロール、酢酸ナトリウム、サリチル酸ナトリウム、サリチル酸フェニル、β−シクロデキストリン、ジブチルヒドロキシトルエン、酒石酸、ショ糖脂肪酸エステル、水酸化カルシウム、水酸化ナトリウム、水酸化マグネシウム、精製ゼラチン、精製大豆レシチン、精製白糖、セスキオレイン酸ソルビタン、セタノール、ゼラチン、ソルビタン脂肪酸エステル、D−ソルビトール、D−ソルビトール液、大豆油不けん化物、デキストラン、天然ビタミンE、トコフェロール、d−δ−トコフェロール、ニコチン酸アミド、乳酸、乳糖、濃グリセリン、白糖、パラオキシ安息香酸エチル、パラオキシ安息香酸ブチル、パラオキシ安息香酸メチル、パントテン酸カルシウム、微結晶セルロース、ヒドロキシプロピルセルロース、氷酢酸、ピロ亜硫酸ナトリウム、ブチルヒドロキシアニソール、ブドウ糖、フマル酸、フマル酸一ナトリウム、プロピレングリコール、ベントナイト、ホウ酸、没食子酸プロピル、ポビドン、ポリアクリル酸部分中和物、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレンポリオキシプロピレングリコール、ポリソルベート、ポリビニルアルコール、ポリビニルアルコール・ジブチルエーテル混合物、マクロゴール、マルトース、マレイン酸、マロン酸、D−マンニトール、無水クエン酸、無水クエン酸ナトリウム、無水ピロリン酸ナトリウム、無水マレイン酸、メタリン酸ナトリウム、メチルセルロース、l−メントール、モノステアリン酸アルミニウム、モノステアリン酸グリセリン、薬用炭、ラウリル硫酸ナトリウム、卵白アルブミン、リュウノウ末、DL−リンゴ酸、などが挙げられる。これらは、1種単独で使用してもよいし、2種以上を併用してもよい。 There is no restriction | limiting in particular as said stabilizer, According to the objective, it can select suitably, For example, adipic acid, ascorbic acid, L-ascorbic acid stearate, L-ascorbic acid sodium, L-aspartic acid, L-sodium aspartate, aminoethylsulfonic acid, DL-alanine, sodium bisulfite, sodium sulfite, L-arginine, sodium alginate, propylene glycol alginate, albumin, benzoic acid, sodium benzoate, sulfur, inositol, fennel powder, ethanol , Calcium edetate, sodium edetate, erythorbic acid, sodium ersorbate, calcium chloride, sodium chloride, magnesium chloride, cysteine hydrochloride, cacao butter, fructose, carboxyvinyl poly -Carmellose calcium, carmellose sodium, hydrous silicon dioxide, dry sodium sulfite, dry aluminum hydroxide gel, dry aluminum hydroxide gel, dry sodium carbonate, xanthan gum, xylitol, citric acid, calcium citrate, sodium citrate, glycine Glycerin, glycerin fatty acid ester, disodium glycyrrhizinate, glucono-δ-lactone, calcium gluconate, light anhydrous silicic acid, cinnamon powder, crystalline cellulose, acetic acid, tocopherol acetate, sodium acetate, sodium salicylate, phenyl salicylate, β-cyclo Dextrin, dibutylhydroxytoluene, tartaric acid, sucrose fatty acid ester, calcium hydroxide, sodium hydroxide, magnesium hydroxide, purified gelatin, purified soybean lecithin Purified sucrose, sorbitan sesquioleate, cetanol, gelatin, sorbitan fatty acid ester, D-sorbitol, D-sorbitol solution, soybean oil unsaponifiable matter, dextran, natural vitamin E, tocopherol, d-δ-tocopherol, nicotinamide, lactic acid , Lactose, concentrated glycerin, sucrose, ethyl paraoxybenzoate, butyl paraoxybenzoate, methyl paraoxybenzoate, calcium pantothenate, microcrystalline cellulose, hydroxypropylcellulose, glacial acetic acid, sodium pyrosulfite, butylhydroxyanisole, glucose, fumaric acid , Monosodium fumarate, propylene glycol, bentonite, boric acid, propyl gallate, povidone, partially neutralized polyacrylic acid, polyoxyethylene hydrogenated castor oil, polyoxyethylene polio Xylpropylene glycol, polysorbate, polyvinyl alcohol, polyvinyl alcohol / dibutyl ether mixture, macrogol, maltose, maleic acid, malonic acid, D-mannitol, anhydrous citric acid, anhydrous sodium citrate, anhydrous sodium pyrophosphate, maleic anhydride, metalin Examples include sodium acid, methylcellulose, l-menthol, aluminum monostearate, glyceryl monostearate, medicinal charcoal, sodium lauryl sulfate, ovalbumin, agate powder, DL-malic acid, and the like. These may be used individually by 1 type and may use 2 or more types together.
前記pH調整剤としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、クエン酸、クエン酸ナトリウム、グリシン、グルコノ−δ−ラクトン、コハク酸、酢酸、酒石酸、D−酒石酸、水酸化ナトリウム、水酸化マグネシウム、乳酸、乳酸カルシウム、氷酢酸、フマル酸一ナトリウム、マレイン酸、無水クエン酸、DL−リンゴ酸、などが挙げられる。これらは、1種単独で使用してもよいし、2種以上を併用してもよい。 The pH adjuster is not particularly limited and may be appropriately selected depending on the intended purpose. For example, citric acid, sodium citrate, glycine, glucono-δ-lactone, succinic acid, acetic acid, tartaric acid, D-tartaric acid Sodium hydroxide, magnesium hydroxide, lactic acid, calcium lactate, glacial acetic acid, monosodium fumarate, maleic acid, anhydrous citric acid, DL-malic acid, and the like. These may be used individually by 1 type and may use 2 or more types together.
前記防腐剤としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、アミノエチルスルホン酸、安息香酸、安息香酸ナトリウム、エタノール、エデト酸ナトリウム、カンテン、dl−カンフル、クエン酸、クエン酸ナトリウム、サリチル酸、サリチル酸ナトリウム、サリチル酸フェニル、ジブチルヒドロキシトルエン、ソルビン酸、ソルビン酸カリウム、デヒドロ酢酸、デヒドロ酢酸ナトリウム、2−ナフトール、白糖、ハチミツ、パラオキシ安息香酸イソブチル、パラオキシ安息香酸イソプロピル、パラオキシ安息香酸エチル、パラオキシ安息香酸ブチル、パラオキシ安息香酸プロピル、パラオキシ安息香酸メチル、l−メントール、ユーカリ油、などが挙げられる。これらは、1種単独で使用してもよいし、2種以上を併用してもよい。 The preservative is not particularly limited and may be appropriately selected depending on the intended purpose. For example, aminoethylsulfonic acid, benzoic acid, sodium benzoate, ethanol, sodium edetate, agar, dl-camphor, citric acid , Sodium citrate, salicylic acid, sodium salicylate, phenyl salicylate, dibutylhydroxytoluene, sorbic acid, potassium sorbate, dehydroacetic acid, sodium dehydroacetate, 2-naphthol, sucrose, honey, isobutyl paraoxybenzoate, isopropyl paraoxybenzoate, paraoxy Examples thereof include ethyl benzoate, butyl paraoxybenzoate, propyl paraoxybenzoate, methyl paraoxybenzoate, l-menthol, and eucalyptus oil. These may be used individually by 1 type and may use 2 or more types together.
本発明の内服用液剤を調製する方法としては、特に制限はなく、目的に応じて公知の方法の中から適宜選択することができる。
本発明の内服用液剤のpHとしては、特に制限はなく、目的に応じて適宜選択することができるが、例えば、4未満が好ましい。前記pHが4以上であると、前記グルクロノラクトンが不安定になり、分解してしまうことがある。
本発明の内服用液剤の使用方法としては、特に制限はなく、目的に応じて適宜選択することができ、例えば、医薬品、医薬部外品、飲料、などとして好適に使用することができる。
本発明の内服用液剤の摂取量としては、特に制限はなく、目的に応じて適宜選択することができるが、例えば、成人である場合には、前記グルクロノラクトンとして、0.3〜1gを一日に3回経口摂取することが好ましい。
There is no restriction | limiting in particular as a method of preparing the liquid for internal use of this invention, According to the objective, it can select suitably from well-known methods.
There is no restriction | limiting in particular as pH of the liquid for internal use of this invention, Although it can select suitably according to the objective, For example, less than 4 is preferable. If the pH is 4 or more, the glucuronolactone may become unstable and decompose.
There is no restriction | limiting in particular as a usage method of the liquid for internal use of this invention, According to the objective, it can select suitably, For example, it can use suitably as a pharmaceutical, a quasi-drug, a drink, etc.
There is no restriction | limiting in particular as an ingestion amount of the liquid for internal use of this invention, Although it can select suitably according to the objective, For example, when it is an adult, 0.3-1g is mentioned as said glucuronolactone. Preferably taken orally three times a day.
本発明の内服用液剤は、肝機能改善能を有するグルクロノラクトンを配合し、薬液、ドリンク剤等として経口摂取等に好適である。該内服用液剤は、えぐみを抑えるため、保存条件等を厳密にする必要がなく、取扱い易く、長期間に亘って味質が変化せず一定に維持可能である。 The liquid for internal use of the present invention contains glucuronolactone having an ability to improve liver function, and is suitable for oral ingestion as a liquid medicine, a drink or the like. The liquid preparation for internal use does not require strict storage conditions in order to suppress itchiness, is easy to handle, and can be maintained constant without changing the taste quality over a long period of time.
(グルクロノラクトン含有溶液の味質変化防止液剤)
本発明のグルクロノラクトン含有溶液の味質変化防止液剤は、塩酸及びリン酸の少なくともいずれかを含有してなり、必要に応じて適宜選択したその他の成分を有する。
前記グルクロノラクトン及びその他の成分としては、上述した通りである。
(Glucuronolactone-containing solution for preventing taste change)
The taste change preventing liquid of the glucuronolactone-containing solution of the present invention contains at least one of hydrochloric acid and phosphoric acid, and has other components appropriately selected as necessary.
The glucuronolactone and other components are as described above.
前記塩酸及びリン酸の少なくともいずれかにより、前記グルクロノラクトン含有溶液の味質変化防止剤における味質変化が防止される。
前記塩酸及びリン酸としては、上述した通りである。
前記塩酸を単独で使用した場合の前記グルクロノラクトン含有溶液の味質変化防止液剤における前記塩酸の含有量としては、特に制限はなく、目的に応じて適宜選択することができるが、例えば、36%塩酸で、0.2×10−3〜1.0体積%が好ましく、0.2×10−2〜0.5体積%がより好ましい。
At least one of the hydrochloric acid and phosphoric acid prevents a taste change in the taste change inhibitor of the glucuronolactone-containing solution.
The hydrochloric acid and phosphoric acid are as described above.
There is no restriction | limiting in particular as content of the said hydrochloric acid in the taste change prevention liquid agent of the said glucuronolactone containing solution at the time of using the said hydrochloric acid alone, Although it can select suitably according to the objective, for example, 36 % Hydrochloric acid is preferably 0.2 × 10 −3 to 1.0% by volume, more preferably 0.2 × 10 −2 to 0.5% by volume.
前記グルクロノラクトン(mg)と塩酸(ml)との比(グルクロノラクトン:塩酸)としては、特に制限はなく、目的に応じて適宜選択することができるが、例えば、前記塩酸1mlに対して前記グルクロノラクトンが5.0×104mg以下であることが好ましく、2.5×104mg以下がより好ましい。 The ratio of glucuronolactone (mg) to hydrochloric acid (ml) (glucuronolactone: hydrochloric acid) is not particularly limited and may be appropriately selected depending on the intended purpose. The glucuronolactone is preferably 5.0 × 10 4 mg or less, and more preferably 2.5 × 10 4 mg or less.
前記リン酸を単独で使用した場合の前記グルクロノラクトン含有溶液の味質変化防止液剤における前記リン酸の含有量としては、特に制限はなく、目的に応じて適宜選択することができるが、例えば、85%リン酸で、0.4×10―3〜2.0質量%が好ましく、0.4×10−2〜1.5質量%がより好ましい。 The content of the phosphoric acid in the taste change prevention liquid of the glucuronolactone-containing solution when the phosphoric acid is used alone is not particularly limited and can be appropriately selected according to the purpose. 85% phosphoric acid, preferably 0.4 × 10 −3 to 2.0 mass%, more preferably 0.4 × 10 −2 to 1.5 mass%.
前記グルクロノラクトン(mg)とリン酸(mg)との比(グルクロノラクトン:リン酸)としては、特に制限はなく、目的に応じて適宜選択することができるが、例えば、前記リン酸1mgに対して前記グルクロノラクトンが2.5×104mg以下が好ましい。 The ratio of glucuronolactone (mg) to phosphoric acid (mg) (glucuronolactone: phosphoric acid) is not particularly limited and may be appropriately selected depending on the intended purpose. For example, 1 mg of phosphoric acid The glucuronolactone is preferably 2.5 × 10 4 mg or less.
前記塩酸及びリン酸を含有する場合の前記味質変化防止液剤における該塩酸及びリン酸の含有量としては、特に制限はなく、目的に応じて適宜選択することができるが、例えば、前記塩酸の含有量×a+前記リン酸の含有量×b (但し、a+b≧1)、であることが好ましい。 The content of the hydrochloric acid and phosphoric acid in the taste change preventing liquid when containing the hydrochloric acid and phosphoric acid is not particularly limited and may be appropriately selected depending on the intended purpose. It is preferable that the content xa + the phosphoric acid content × b (where a + b ≧ 1).
前記グルクロノラクトン(mg)と、前記塩酸(ml)及びリン酸(mg)との比としては、特に制限はなく、目的に応じて適宜選択することができるが、例えば、前記塩酸a(ml)+前記リン酸2b(mg) (但し、a+b=1)に対して前記グルクロノラクトンが5.0×104mg以下が好ましい。 The ratio of the glucuronolactone (mg) to the hydrochloric acid (ml) and phosphoric acid (mg) is not particularly limited and may be appropriately selected depending on the intended purpose. For example, the hydrochloric acid a (ml ) + Phosphoric acid 2b (mg) (where a + b = 1), but the glucuronolactone is preferably 5.0 × 10 4 mg or less.
本発明の前記グルクロノラクトン含有溶液の味質変化防止液剤は、前記塩酸及びリン酸の少なくともいずれかを含有することにより、保存条件等を厳密にする必要がなく、取扱い易く、長期間に亘って前記グルクロノラクトンによる味質変化を抑制し、味質を一定に維持可能である。 The taste change preventing liquid of the glucuronolactone-containing solution of the present invention contains at least one of the hydrochloric acid and phosphoric acid, so that it is not necessary to strictly preserve storage conditions and the like, and is easy to handle and can be used for a long time. Thus, it is possible to keep the taste quality constant by suppressing the taste change caused by the glucuronolactone.
以下、実施例により本発明を更に具体的に説明するが、本発明はこれらに限定されるものではない。 EXAMPLES Hereinafter, the present invention will be described more specifically with reference to examples, but the present invention is not limited thereto.
(実施例1〜4及び比較例1〜4) (Examples 1-4 and Comparative Examples 1-4)
−内服用液剤の調製−
下記表1に示す組成及びpHになるように50mlの内服用液剤を常法により調製した。なお、比較例1〜3では、DL−リンゴ酸とクエン酸との混合物(DL−リンゴ酸:クエン酸=2:1(質量比))を適量加えることによりpHを2.70に調整した。
-Preparation of liquid for internal use-
50 ml of an internal use liquid preparation was prepared by a conventional method so as to have the composition and pH shown in Table 1 below. In Comparative Examples 1 to 3, the pH was adjusted to 2.70 by adding an appropriate amount of a mixture of DL-malic acid and citric acid (DL-malic acid: citric acid = 2: 1 (mass ratio)).
−評価(pH)−
得られた各内服用液剤を遮光ビンに入れ、60℃の条件下で2週間放置した(以下、得られた内服用液剤を「60℃2W」と表すことがある)。また、同様にして、50℃の条件下で1ヶ月放置した(以下、得られた内服用液剤を「50℃1M」と表すことがある)。これらの内服用液剤のpHを測定したところ、表2に示す通りとなった。
-Evaluation (pH)-
Each obtained liquid for internal use was placed in a light-shielding bottle and allowed to stand for 2 weeks at 60 ° C. (hereinafter, the obtained liquid for internal use may be referred to as “60 ° C. 2 W”). Similarly, it was left for 1 month under the condition of 50 ° C. (hereinafter, the obtained liquid for internal use may be expressed as “50 ° C. 1M”). When the pH of these liquids for internal use was measured, it was as shown in Table 2.
−評価(酸味)−
7人のパネラーが、調製直後と同じ内服用液剤、及び60℃の条件下で2週間放置した内服用液剤を、この順に飲み、前記調製直後の内服用液剤と比べた酸味の差について評価した。結果を表3に示す。
-Evaluation (acidity)-
Seven panelists swallowed the same internal liquids immediately after preparation and internal liquids left for 2 weeks at 60 ° C. in this order, and evaluated the difference in sourness compared to the internal liquid immediately after the preparation. . The results are shown in Table 3.
また、7人のパネラーが、調製直後と同じ内服用液剤、及び50℃の条件下で1ヶ月間放置した内服用液剤を、この順に飲み、前記調製直後の内服用液剤と比べた酸味の感じ方(味質の変化)について評価した。結果を表4に示す。 In addition, seven panelists drank the same internal liquid preparation immediately after preparation and the internal liquid preparation left for one month under the condition of 50 ° C. in this order, and the sour taste compared to the internal preparation liquid immediately after the preparation. The method (change in taste quality) was evaluated. The results are shown in Table 4.
表3及び表4より、比較例1及び4の内服用液剤の結果から、グルクロノラクトンを含有していない場合、酸味、味質の経時変化がなかったことから、グルクロノラクトンが影響し、酸味を伴う「えぐみ」が生じ、味質が変化するものと推測された。また、比較例2及び比較例3の内服用液剤の結果から、グルクロノラクトンを含有する場合であって、塩酸を含有していない場合には、経時的に「えぐみ」が生じ、味質が変化することが判る。一方、実施例1〜4の内服用液剤の結果から、塩酸を含有している場合には、酸味を伴う「えぐみ」が経時的に生ずることがなく、味質が変化せず一定であることが判る。 From Table 3 and Table 4, from the results of the liquids for internal use in Comparative Examples 1 and 4, when glucuronolactone was not contained, there was no change in sourness and taste over time, so glucuronolactone affected, It was speculated that “gumami” accompanied by sourness occurred and the taste quality changed. Further, from the results of the liquid preparations for internal use of Comparative Example 2 and Comparative Example 3, when glucuronolactone was contained and hydrochloric acid was not contained, “egumi” was produced over time, and the taste quality Can be seen to change. On the other hand, from the results of the internal use liquid preparations of Examples 1 to 4, when hydrochloric acid is contained, “egumi” accompanied by sourness does not occur over time, and the taste quality does not change and is constant. I understand that.
(実施例5〜7)
実施例1において、内服用液剤を下記表5に示す組成に常法により調製した内服用液剤に代えた以外は実施例1と同様にして酸味の評価を行った。60℃の条件下で2週間放置した場合の評価結果を表6に示し、50℃の条件下で1ヶ月間放置した場合の評価結果を表7に示す。
(Examples 5-7)
In Example 1, the sourness was evaluated in the same manner as in Example 1 except that the liquid for internal use was replaced with the liquid for internal use prepared by a conventional method in the composition shown in Table 5 below. The evaluation results when left for 2 weeks at 60 ° C. are shown in Table 6, and the evaluation results when left for 1 month at 50 ° C. are shown in Table 7.
本発明の内服用液剤は、グルクロノラクトンを含有しているため、医療業等の分野で利用することができ、例えば、医薬品、医薬部外品、飲料、などとして好適に使用することができる。本発明のグルクロノラクトン含有溶液の味質変化防止液剤は、塩酸及びリン酸の少なくともいずれかを含有しているため、グルクロノラクトンを含有する、医薬品、医薬部外品、飲料、などに好適に使用することができる。
Since the liquid for internal use of the present invention contains glucuronolactone, it can be used in fields such as the medical industry, and can be suitably used as, for example, pharmaceuticals, quasi drugs, beverages, and the like. . The solution for preventing change in taste of a glucuronolactone-containing solution of the present invention contains at least one of hydrochloric acid and phosphoric acid, and is therefore suitable for pharmaceuticals, quasi-drugs, beverages and the like containing glucuronolactone. Can be used for
Claims (6)
A taste change preventing liquid for a glucuronolactone-containing solution, characterized by containing at least one of hydrochloric acid and phosphoric acid.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004055319A JP4694132B2 (en) | 2003-09-12 | 2004-02-27 | Liquid for internal use and liquid for preventing change in taste of glucuronolactone-containing solution |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003321771 | 2003-09-12 | ||
JP2003321771 | 2003-09-12 | ||
JP2004055319A JP4694132B2 (en) | 2003-09-12 | 2004-02-27 | Liquid for internal use and liquid for preventing change in taste of glucuronolactone-containing solution |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005104960A true JP2005104960A (en) | 2005-04-21 |
JP4694132B2 JP4694132B2 (en) | 2011-06-08 |
Family
ID=34554398
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004055319A Expired - Lifetime JP4694132B2 (en) | 2003-09-12 | 2004-02-27 | Liquid for internal use and liquid for preventing change in taste of glucuronolactone-containing solution |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4694132B2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007077656A1 (en) * | 2005-12-28 | 2007-07-12 | Lion Corporation | Liquid medicine for internal use |
JP2007176852A (en) * | 2005-12-28 | 2007-07-12 | Lion Corp | Liquid composition for oral administration |
JP2008105992A (en) * | 2006-10-25 | 2008-05-08 | Lion Corp | Product of internal liquid agent |
JP2008162900A (en) * | 2006-12-27 | 2008-07-17 | Lion Corp | Liquid medicine composition for oral administration |
JP2009149578A (en) * | 2007-12-21 | 2009-07-09 | Lion Corp | Composition for internal use |
JP2011132156A (en) * | 2009-12-24 | 2011-07-07 | Lion Corp | Oral liquid composition |
JP2011136949A (en) * | 2009-12-28 | 2011-07-14 | Lion Corp | Liquid composition for oral administration |
WO2014192792A1 (en) * | 2013-05-30 | 2014-12-04 | 大正製薬株式会社 | Liquid preparation for internal use |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04117328A (en) * | 1990-09-05 | 1992-04-17 | Chugai Pharmaceut Co Ltd | Body lipid storage-reducing agent |
JPH10298093A (en) * | 1997-04-24 | 1998-11-10 | Chugai Pharmaceut Co Ltd | Liquid medicine for internal use |
JPH11217329A (en) * | 1998-01-30 | 1999-08-10 | Sanpo Seiyaku Kk | Solidified analeptic |
JP2002080375A (en) * | 2000-09-04 | 2002-03-19 | Taisho Pharmaceut Co Ltd | Oral liquid medicine formulated with iron compound |
JP2003055194A (en) * | 2001-08-16 | 2003-02-26 | Taiho Yakuhin Kogyo Kk | Internal liquid medicine |
-
2004
- 2004-02-27 JP JP2004055319A patent/JP4694132B2/en not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04117328A (en) * | 1990-09-05 | 1992-04-17 | Chugai Pharmaceut Co Ltd | Body lipid storage-reducing agent |
JPH10298093A (en) * | 1997-04-24 | 1998-11-10 | Chugai Pharmaceut Co Ltd | Liquid medicine for internal use |
JPH11217329A (en) * | 1998-01-30 | 1999-08-10 | Sanpo Seiyaku Kk | Solidified analeptic |
JP2002080375A (en) * | 2000-09-04 | 2002-03-19 | Taisho Pharmaceut Co Ltd | Oral liquid medicine formulated with iron compound |
JP2003055194A (en) * | 2001-08-16 | 2003-02-26 | Taiho Yakuhin Kogyo Kk | Internal liquid medicine |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007077656A1 (en) * | 2005-12-28 | 2007-07-12 | Lion Corporation | Liquid medicine for internal use |
JP2007176852A (en) * | 2005-12-28 | 2007-07-12 | Lion Corp | Liquid composition for oral administration |
JP5295571B2 (en) * | 2005-12-28 | 2013-09-18 | ライオン株式会社 | Solution for internal use for fatigue recovery |
KR101326397B1 (en) * | 2005-12-28 | 2013-11-11 | 라이온 가부시키가이샤 | Liquid medicine for internal use |
JP2008105992A (en) * | 2006-10-25 | 2008-05-08 | Lion Corp | Product of internal liquid agent |
JP2008162900A (en) * | 2006-12-27 | 2008-07-17 | Lion Corp | Liquid medicine composition for oral administration |
JP2009149578A (en) * | 2007-12-21 | 2009-07-09 | Lion Corp | Composition for internal use |
JP2011132156A (en) * | 2009-12-24 | 2011-07-07 | Lion Corp | Oral liquid composition |
JP2011136949A (en) * | 2009-12-28 | 2011-07-14 | Lion Corp | Liquid composition for oral administration |
WO2014192792A1 (en) * | 2013-05-30 | 2014-12-04 | 大正製薬株式会社 | Liquid preparation for internal use |
JPWO2014192792A1 (en) * | 2013-05-30 | 2017-02-23 | 大正製薬株式会社 | Oral solution |
Also Published As
Publication number | Publication date |
---|---|
JP4694132B2 (en) | 2011-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3657203B2 (en) | Copper chlorophyllin salt-containing liquid composition | |
JPWO2009099132A1 (en) | Method for improving storage stability of glutathione | |
JP5295571B2 (en) | Solution for internal use for fatigue recovery | |
JP4694132B2 (en) | Liquid for internal use and liquid for preventing change in taste of glucuronolactone-containing solution | |
JP2003026576A (en) | Medicine having improved taste | |
JP6093343B2 (en) | Liquid for internal use | |
JP5766021B2 (en) | Stable aqueous solution | |
JP3805646B2 (en) | Pharmaceutical solution | |
TWI837375B (en) | Water soluble o-glycosyl flavonoid compositions and methods for preparing same | |
JP4068442B2 (en) | Taste improving composition | |
JP2007153833A (en) | Oral administration composition | |
JP5422370B2 (en) | Oral liquid composition | |
JP5461984B2 (en) | Oral liquid composition | |
JP4206506B2 (en) | Solution containing vitamin B1 | |
JP5298526B2 (en) | Composition for internal use | |
JP4514398B2 (en) | Pharmaceutical composition for internal use | |
JP2006045217A (en) | Zinc-containing composition for oral administration | |
JP2008088116A (en) | Aqueous liquid preparation composition for internal use | |
JP5412708B2 (en) | Liquid composition for internal use | |
WO2017086425A1 (en) | Biotin-containing liquid agent | |
JP4932253B2 (en) | Oral liquid composition | |
JP5266644B2 (en) | Ascorbic acid-containing liquid | |
JP4228403B2 (en) | Solution containing vitamin B1 | |
JP2016121088A (en) | Liquid agent for internal use | |
CA3213851A1 (en) | Liquid preparation of l-serine or pharmaceutically acceptable salt thereof and method for preparing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20060720 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060919 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061006 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100202 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100405 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110125 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110223 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140304 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4694132 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |